Circulating biomarkers predictive of postoperative atrial fibrillation

Cardiology in Review

Volumn 24, Issue 2, 2016, Pages 76-87

  Turagam, Mohit K ^a,b   Mirza, Mahek ^a   Werner, Paul H ^c   Sra, Jasbir ^d   Kress, David C ^c   Tajik, A Jamil ^d   Jahangir, Arshad ^a,d  

^a AURORA HEALTH CARE   (United States)

^b University of Missouri   (United States)

^c ST LUKE S MEDICAL CENTER   (United States)

^d AURORA SINAI MEDICAL CENTER   (United States)

Author keywords

Atrial fibrosis; Atrial remodeling; Biomarkers; BNP; Cardiac surgery; Collagen; Micro RNA; Postoperative atrial fibrillation

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; COLLAGEN; COLLAGEN TYPE 1; COLLAGENASE 3; CONNECTIVE TISSUE GROWTH FACTOR; FAS ANTIGEN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MICRORNA; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA1;

ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CELL DEATH; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART SURGERY; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; POSTOPERATIVE ATRIAL FIBRILLATION; PREOPERATIVE COMPLICATION; PROTEIN BLOOD LEVEL; REVIEW; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; BLOOD; POSTOPERATIVE COMPLICATION; PROGNOSIS;

ATRIAL FIBRILLATION; BIOMARKERS; CARDIAC SURGICAL PROCEDURES; HUMANS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS;

EID: 84958068679     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000059     Document Type: Review

References (154)

1. Echahidi N, Pibarot P, O'Hara G, et al. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51:793-801.
2. Villareal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol. 2004;43:742-748.
3. Hakala T, Hedman A, Turpeinen A, et al. Prediction of atrial fibrillation after coronary artery bypass grafting by measuring atrial peptide levels and preoperative atrial dimensions. Eur J Cardiothorac Surg. 2002;22:939-943.
4. Mathew JP, Fontes ML, Tudor IC, et al; Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004;291:1720-1729.
5. Maesen B, Nijs J, Maessen J, et al. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012;14:159-174.
6. Christians KK, Wu B, Quebbeman EJ, et al. Postoperative atrial fibrillation in noncardiothoracic surgical patients. Am J Surg. 2001;182:713-715.
7. Shen J, Lall S, Zheng V, et al. The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades. J Thorac Cardiovasc Surg. 2011;141:559-570.
8. Kahn RL, Hargett MJ, Urquhart B, et al. Supraventricular tachyarrhythmias during total joint arthroplasty. Incidence and risk. Clin Orthop Relat Res. 1993; (296): 265-9.
9. Voigt N, Heijman J, Wang Q, et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation. 2014;129:145-156.
10. El-Chami MF, Kilgo P, Thourani V, et al. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am Coll Cardiol. 2010;55:1370-1376.
11. Mariscalco G, Engström KG. Postoperative atrial fibrillation is associated with late mortality after coronary surgery, but not after valvular surgery. Ann Thorac Surg. 2009;88:1871-1876.
12. Ahlsson A, Fengsrud E, Bodin L, et al. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg. 2010;37:1353-1359.
13. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-3548.
14. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics.2014 update: a report from the American Heart Association. Circulation. 2014;129:e28-e292.
15. Jacob KA, Nathoe HM, Dieleman JM, et al. Inflammation in new-onset atrial fibrillation after cardiac surgery: a systematic review. Eur J Clin Invest. 2014;44:402-428.
16. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1. 76.
17. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335-2345.
18. Amar D, Zhang H, Miodownik S, et al. Competing autonomic mechanisms precede the onset of postoperative atrial fibrillation. J Am Coll Cardiol. 2003;42:1262-1268.
19. Gaudino M, Andreotti F, Zamparelli R, et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation. 2003;108(Suppl 1):II195-9.
20. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263-2270.
21. Ishii Y, Schuessler RB, Gaynor SL, et al. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. 2005;111:2881-2888.
22. Tanawuttiwat T, O'Neill BP, Cohen MG, et al. New-onset atrial fibrillation after aortic valve replacement: comparison of transfemoral, transapical, transaortic, and surgical approaches. J Am Coll Cardiol. 2014;63:1510-1519.
23. Rodrigo R, Korantzopoulos P, Cereceda M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol. 2013;62:1457-1465.
24. Ad N, Snir E, Vidne BA, et al. Histologic atrial myolysis is associated with atrial fibrillation after cardiac operation. Ann Thorac Surg. 2001;72:688-693.
25. Mariscalco G, Engstrom KG, Ferrarese S, et al. Relationship between atrial histopathology and atrial fibrillation after coronary bypass surgery. J Thorac Cardiovasc Surg. 2006;131:1364-1372.
26. Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453-1468.
27. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802-809.
28. Darbar D, Jahangir A, Hammill SC, et al. P wave signal-averaged electrocardiography to identify risk for atrial fibrillation. Pacing Clin Electrophysiol. 2002;25:1447-1453.
29. Hoit BD. Left atrial size and function: role in prognosis. J Am Coll Cardiol. 2014;63:493-505.
30. Swartz MF, Fink GW, Lutz CJ, et al. Left versus right atrial difference in dominant frequency, K (+) channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery. Heart Rhythm. 2009;6:1415-1422.
31. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation. 2007;115:3050-3056.
32. Jahangir A, Murarka S. Progression of paroxysmal to persistent atrial fibrillation factors promoting the HATCH score. J Am Coll Cardiol. 2010;55:732-734.
33. Melduni RM, Suri RM, Seward JB, et al. Diastolic dysfunction in patients undergoing cardiac surgery: a pathophysiological mechanism underlying the initiation of new-onset post-operative atrial fibrillation. J Am Coll Cardiol. 2011;58:953-961.
34. Turagam MK, Downey FX, Kress DC, Sra J, Tajik AJ, Jahangir A. Pharmacological strategies for prevention of postoperative atrial fibrillation. Expert Rev Clin Pharmacol. 2015;8:233-250.
35. Mirza M, Strunets A, Shen WK, et al. Mechanisms of arrhythmias and conduction disorders in older adults. Clin Geriatr Med. 2012;28:555-573.
36. McManus DD, Lin H, Tanriverdi K, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Heart Rhythm. 2014;11:663-669.
37. Todaro MC, Choudhuri I, Belohlavek M, et al. New echocardiographic techniques for evaluation of left atrial mechanics. Eur Heart J Cardiovasc Imaging. 2012;13:973-984.
38. Wachtell K, Greve AM. Structural and functional cardiac changes are target organ damage that increases risk of atrial fibrillation. J Am Coll Cardiol. 2014;63:2014-2015.
39. Kornej J, Apostolakis S, Bollmann A, et al. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29:1181-1193.
40. Wyse DG, Van Gelder IC, Ellinor PT, et al. Lone atrial fibrillation: does it exist? J Am Coll Cardiol. 2014;63:1715-1723.
41. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol. 2003;41:2185-2192.
42. Montaigne D, Marechal X, Lefebvre P, et al. Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops. J Am Coll Cardiol. 2013;62:1466-1473.
43. Rader F, Van Wagoner DR, Ellinor PT, et al. Influence of race on atrial fibrillation after cardiac surgery. Circ Arrhythm Electrophysiol. 2011;4:644-652.
44. Zacharias A, Schwann TA, Riordan CJ, et al. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation. 2005;112:3247-3255.
45. Kernis SJ, Nkomo VT, Messika-Zeitoun D, et al. Atrial fibrillation after surgical correction of mitral regurgitation in sinus rhythm: incidence, outcome, and determinants. Circulation. 2004;110:2320-2325.
46. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34:2731-2738.
47. Kanagaratnam P, Kojodjojo P, Peters NS. Electrophysiological abnormalities occur prior to the development of clinical episodes of atrial fibrillation: observations from human epicardial mapping. Pacing Clin Electrophysiol. 2008;31:443-453.
48. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001;344:1043-1051.
49. Jahangir A, Hammill SC. Parasympathetics and atrial fibrillation. J Cardiovasc Electrophysiol. 2005;16:885-887.
50. Fleming GA, Murray KT, Yu C, et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation. 2008;118:1619-1625.
51. Sampson KJ, Terrenoire C, Cervantes DO, et al. Adrenergic regulation of a key cardiac potassium channel can contribute to atrial fibrillation: evidence from an I Ks transgenic mouse. J Physiol. 2008;586:627-637.
52. Dobrev D, Wettwer E, Kortner A, et al. Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc Res. 2002;54:397-404.
53. Brandt MC, Priebe L, Bohle T, et al. The ultrarapid and the transient outward K (+) current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J Mol Cell Cardiol. 2000;32:1885-1896.
54. Brundel BJ, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation. 2001;103:684-690.
55. Dupont E, Ko Y, Rothery S, et al. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation. 2001;103:842-849.
56. Ak K, Akgun S, Tecimer T, et al. Determination of histopathologic risk factors for postoperative atrial fibrillation in cardiac surgery. Ann Thorac Surg. 2005;79:1970-1975.
57. Mirza M, Strunets A, Holmuhamedov E, et al. A novel histology based classification system to identify patients at risk of postoperative atrial fibrillation. Circ Res. 2013;113:A038.
58. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010;121:1645-1654.
59. Rahmutula D, Marcus GM, Wilson EE, et al. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. Cardiovasc Res. 2013;99:769-779.
60. Ma Y, de Castro Bras LE, Toba H, et al. Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch. 2014;466:1113-1127.
61. He X, Gao X, Peng L, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res. 2011;108:164-175.
62. Swartz MF, Fink GW, Sarwar MF, et al. Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. J Am Coll Cardiol. 2012;60:1799-1806.
63. Nakajima H, Nakajima HO, Salcher O, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta (1) transgene in the heart. Circ Res. 2000;86:571-579.
64. Nakatani Y, Nishida K, Sakabe M, et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction. J Am Coll Cardiol. 2013;61:582-588.
65. Erratum in: J Am Coll Cardiol 2013;62:2260.
66. Lee KW, Everett TH 4th, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114:1703-1712.
67. Hao J, Wang B, Jones SC, et al. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol. 2000;279:H3020-H3030.
68. Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299-2307.
69. Goette A, Schon N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5:43-51.
70. Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
71. Erratum in: Eur Heart J 2013;34:790;
72. Eur Heart J 2013;34:2850-2851.
73. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1935-1944.
74. Gramley F, Lorenzen J, Koellensperger E, et al. Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway. Int J Cardiol. 2010;143:405-413.
75. On YK, Jeon ES, Lee SY, et al. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure. J Thorac Cardiovasc Surg. 2009;137:1515-1520.
76. Kim SK, Pak HN, Park JH, et al. Clinical and serological predictors for the recurrence of atrial fibrillation after electrical cardioversion. Europace. 2009;11:1632-1638.
77. Kim SK, Park JH, Kim JY, et al. High plasma concentrations of transforming growth factor-β and tissue inhibitor of metalloproteinase-1: potential noninvasive predictors for electroanatomical remodeling of atrium in patients with non-valvular atrial fibrillation. Circ J. 2011;75:557-564.
78. Erratum in: Circ J 2011;75:1013.
79. Behnes M, Hoffmann U, Lang S, et al. Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol. 2011;100:335-342.
80. Kassiri Z, Khokha R. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost. 2005;93:212-219.
81. Jun. JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 2011;10:945-963.
82. Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006;97:532-537.
83. Kallergis EM, Manios EG, Kanoupakis EM, et al. Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. J Am Coll Cardiol. 2008;52:211-215.
84. Neuberger HR, Cacciatore A, Reil JC, et al. Procollagen propeptides: serum markers for atrial fibrosis? Clin Res Cardiol. 2012;101:655-661.
85. Lopez B, Gonzalez A, Querejeta R, et al. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens. 2005;23:1445-1451.
86. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000;101:1729-1735.
87. Lopez B, Gonzalez A, Beaumont J, et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:859-867.
88. Huxley RR, Lopez FL, MacLehose RF, et al. Novel association between plasma matrix metalloproteinase-9 and risk of incident atrial fibrillation in a case-cohort study: the Atherosclerosis Risk in Communities study. PLoS One. 2013;8:e59052.
89. Tziakas DN, Chalikias GK, Papanas N, et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace. 2007;9:589-596.
90. Nakano Y, Niida S, Dote K, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004;43:818-825.
91. Anne W, Willems R, Roskams T, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res. 2005;67:655-666.
92. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004;109:363-368.
93. Kalogeropoulos AS, Tsiodras S, Rigopoulos AG, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011;11:77.
94. Li Y, Jian Z, Yang ZY, et al. Increased expression of connective tissue growth factor and transforming growth factor-beta-1 in atrial myocardium of patients with chronic atrial fibrillation. Cardiology. 2013;124:233-240.
95. Adam O, Lavall D, Theobald K, et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol. 2010;55:469-480.
96. Song ZP, Liu X, Zhang DD. Connective tissue growth factor: a predictor of recurrence after catheter ablation in patients with nonparoxysmal atrial fibrillation. Pacing Clin Electrophysiol. 2014;37:630-637.
97. Rudolph V, Andrie RP, Rudolph TK, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med. 2010;16:470-474.
98. Letsas KP, Filippatos GS, Pappas LK, et al. Determinants of plasma NT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol. 2009;98:101-106.
99. Pfister R, Scholz M, Wielckens K, et al. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail. 2004;6:289-293.
100. Patton KK, Heckbert SR, Alonso A, et al. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart. 2013;99:1832-1836.
101. Cao H, Zhou Q, Wu Y, et al. Preoperative serum soluble receptor activator of nuclear factor-κB ligand and osteoprotegerin predict postoperative atrial fibrillation in patients undergoing cardiac valve surgery. Ann Thorac Surg. 2013;96:800-806.
102. Kaireviciute D, Blann AD, Balakrishnan B, et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost. 2010;104:122-127.
103. Marott SC, Nordestgaard BG, Zacho J, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47, 000 individuals from the general population. J Am Coll Cardiol. 2010;56:789-795.
104. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50:2021-2028.
105. Ko WC, Hong CY, Hou SM, et al. Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. Circ J. 2011;75:1592-1600.
106. Matsui Y, Sadoshima J. Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy. J Mol Cell Cardiol. 2004;37:477-481.
107. Kiryu M, Niwano S, Niwano H, et al. Angiotensin II-mediated up-regulation of connective tissue growth factor promotes atrial tissue fibrosis in the canine atrial fibrillation model. Europace. 2012;14:1206-1214.
108. Chen MM, Lam A, Abraham JA, et al. CTGF expression is induced by TGFbeta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol. 2000;32:1805-1819.
109. Dean RG, Balding LC, Candido R, et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem. 2005;53:1245-1256.
110. Panek AN, Posch MG, Alenina N, et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One. 2009;4:e6743.
111. Hayata N, Fujio Y, Yamamoto Y, et al. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun. 2008;370:274-278.
112. Yabluchanskiy A, Ma Y, Chiao YA, et al. Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2014;306:H1398-H1407.
113. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46:214-224.
114. Boixel C, Fontaine V, Rucker-Martin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 2003;42:336-344.
115. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol. 2004;44:740-749.
116. Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34:1475-1480.
117. Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768-1774.
118. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
119. Gasparovic H, Burcar I, Kopjar T, et al. NT-pro-BNP, but not C-reactive protein, is predictive of atrial fibrillation in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg. 2010;37:100-105.
120. Cai GL, Chen J, Hu CB, et al. Value of plasma brain natriuretic peptide levels for predicting postoperative atrial fibrillation: a systemic review and metaanalysis. World J Surg. 2014;38:51-59.
121. Rossi A, Enriquez-Sarano M, Burnett JC Jr, et al. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000;35:1256-1262.
122. Yoshihara F, Nishikimi T, Sasako Y, et al. Plasma atrial natriuretic peptide concentration inversely correlates with left atrial collagen volume fraction in patients with atrial fibrillation: plasma ANP as a possible biochemical marker to predict the outcome of the maze procedure. J Am Coll Cardiol. 2002;39:288-294.
123. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47:345-353.
124. Anselmi A, Possati G, Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg. 2009;88:326-333.
125. Ho KM, Tan JA. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation. 2009;119:1853-1866.
126. Liakopoulos OJ, Choi YH, Kuhn EW, et al. Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. J Thorac Cardiovasc Surg. 2009;138:678-686. e1.
127. Imazio M, Brucato A, Ferrazzi P, et al; COPPS Investigators. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011;124:2290-2295.
128. Hueb W, Lopes NH, Pereira AC, et al. Five-year follow-up of a randomized comparison between off-pump and on-pump stable multivessel coronary artery bypass grafting. The MASS III Trial. Circulation. 2010;122(11 Suppl):S48-S52.
129. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation. 1997;95:511-521.
130. Ramlawi B, Otu H, Mieno S, et al. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann Thorac Surg. 2007;84:1166-72; discussion 1172.
131. Légaré JF, Buth KJ, King S, et al. Coronary bypass surgery performed off pump does not result in lower in-hospital morbidity than coronary artery bypass grafting performed on pump. Circulation. 2004;109:887-892.
132. Panesar SS, Athanasiou T, Nair S, et al. Early outcomes in the elderly: a meta-analysis of 4921 patients undergoing coronary artery bypass grafting-comparison between off-pump and on-pump techniques. Heart. 2006;92:1808-1816.
133. Ryu K, Li L, Khrestian CM, et al. Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmias. Am J Physiol Heart Circ Physiol. 2007;293:H1231-H1241.
134. Schnabel RB, Larson MG, Yamamoto JF, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol. 2009;104:92-96.
135. Heinke MY, Yao M, Chang D, et al. Apoptosis of ventricular and atrial myocytes from pacing-induced canine heart failure. Cardiovasc Res. 2001;49:127-134.
136. Müller P, Deneke T, Schiedat F, et al. Increased preoperative serum apoptosis marker fas ligand correlates with histopathology and new-onset of atrial fibrillation in patients after cardiac surgery. J Cardiovasc Electrophysiol. 2013;24:1110-1115.
137. Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation. Circ Res. 2014;114:1469-1482.
138. Body SC, Collard CD, Shernan SK, et al. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circ Cardiovasc Genet. 2009;2:499-506.
139. Voudris KV, Apostolakis S, Karyofillis P, et al. Genetic diversity of the KCNE1 gene and susceptibility to postoperative atrial fibrillation. Am Heart J. 2014;167:274-280. e1.
140. Lu Y, Zhang Y, Wang N, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122:2378-2387.
141. Erratum in: Circulation. 2011;124:e334.
142. Xiao J, Liang D, Zhang Y, et al. MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol Genomics. 2011;43:655-664.
143. Dawson K, Wakili R, Ordög B, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. 2013;127:1466-1475, 1475e1.
144. Xu GJ, Gan TY, Tang BP, et al. Accelerated fibrosis and apoptosis with ageing and in atrial fibrillation: adaptive responses with maladaptive consequences. Exp Ther Med. 2013;5:723-729.
145. Nishi H, Sakaguchi T, Miyagawa S, et al. Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS One. 2013;8:e73397.
146. Cardin S, Guasch E, Luo X, et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol. 2012;5:1027-1035.
147. Li H, Li S, Yu B, et al. Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. Mol Med Rep. 2012;5:1457-1460.
148. Dobrev D. Is altered atrial microRNA-ome a critical contributor to the pathophysiology of atrial fibrillation? Basic Res Cardiol. 2012;107:284.
149. Liu Z, Zhou C, Liu Y, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One. 2012;7:e44906.
150. Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol. 2012;107:278.
151. Girmatsion Z, Biliczki P, Bonauer A, et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Heart Rhythm. 2009;6:1802-1809.
152. Mannello F. Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol. 2008;28:611-614.
153. Jung K, Klotzek S, Stephan C, et al. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem. 2008;54:772-773.
154. Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17:764-769.